AngioDynamics (NASDAQ:ANGO) Posts Earnings Results, Misses Expectations By $0.05 EPS

AngioDynamics (NASDAQ:ANGO) issued its quarterly earnings data on Tuesday. The medical instruments supplier reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.05), RTT News reports. AngioDynamics had a negative return on equity of 3.16% and a negative net margin of 10.67%.The firm had revenue of $79.43 million during the quarter, compared to analyst estimates of $76.43 million. During the same quarter in the prior year, the firm earned ($0.04) EPS. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. AngioDynamics updated its FY 2026 guidance to -0.330–0.230 EPS.

Here are the key takeaways from AngioDynamics’ conference call:

• Revenue grew 8.8% to $79.4M, adjusted EBITDA nearly doubled to $5.9M, the company generated $4.7M of cash in the quarter, and management raised FY26 guidance to $312–314M in sales and $8–10M of adjusted EBITDA.
• The Med Tech segment drove performance — Med Tech revenue was up 13% and now represents 45% of sales, with Auryon up 18.6% marking its 18th consecutive quarter of double‑digit growth and initial international contribution after CE Mark approval.
• Meaningful regulatory progress in mechanical thrombectomy — IDE approvals for the APEX Return (AlphaReturn blood‑management) and PAVE (AngioVac for right‑heart vegetation) studies plus a 510(k) expanding AlphaVac indications, broadening clinical use and competitive positioning.
• NanoKnife momentum — revenue +22.2% (probe growth +14.4%), a record quarter for prostate procedures, and the new CPT code effective Jan 1 should support adoption over time.
• CEO Jim Clemmer announced his planned retirement with a board search for a successor in fiscal 2027; he will remain through the transition, but the change introduces leadership‑transition risk.

AngioDynamics Stock Performance

Shares of NASDAQ:ANGO traded down $1.55 during trading hours on Tuesday, hitting $11.68. 1,630,344 shares of the company’s stock traded hands, compared to its average volume of 941,490. The company’s fifty day simple moving average is $12.69 and its two-hundred day simple moving average is $11.00. The company has a market cap of $481.38 million, a price-to-earnings ratio of -14.93 and a beta of 0.47. AngioDynamics has a 52 week low of $8.27 and a 52 week high of $13.99.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on ANGO shares. Wall Street Zen lowered shares of AngioDynamics from a “buy” rating to a “hold” rating in a research note on Sunday, December 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday, October 8th. Finally, Canaccord Genuity Group raised their target price on shares of AngioDynamics from $17.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, October 3rd. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $19.33.

Insiders Place Their Bets

In other news, SVP Lawrence T. Weiss bought 10,000 shares of the company’s stock in a transaction dated Tuesday, October 21st. The shares were acquired at an average cost of $11.81 per share, with a total value of $118,100.00. Following the completion of the transaction, the senior vice president directly owned 93,597 shares in the company, valued at approximately $1,105,380.57. The trade was a 11.96% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO James C. Clemmer acquired 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 9th. The stock was purchased at an average cost of $11.15 per share, with a total value of $111,500.00. Following the purchase, the chief executive officer directly owned 882,529 shares in the company, valued at approximately $9,840,198.35. This trade represents a 1.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 20,890 shares of company stock valued at $239,532 in the last quarter. Insiders own 6.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. increased its stake in shares of AngioDynamics by 9.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier’s stock worth $2,434,000 after purchasing an additional 22,658 shares during the last quarter. Jane Street Group LLC raised its holdings in AngioDynamics by 267.1% during the first quarter. Jane Street Group LLC now owns 46,803 shares of the medical instruments supplier’s stock valued at $439,000 after buying an additional 34,054 shares in the last quarter. Legal & General Group Plc lifted its position in shares of AngioDynamics by 279.5% in the second quarter. Legal & General Group Plc now owns 12,353 shares of the medical instruments supplier’s stock worth $123,000 after buying an additional 9,098 shares during the last quarter. Rhumbline Advisers lifted its position in shares of AngioDynamics by 4.3% in the second quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier’s stock worth $608,000 after buying an additional 2,510 shares during the last quarter. Finally, American Century Companies Inc. boosted its stake in shares of AngioDynamics by 15.8% during the 2nd quarter. American Century Companies Inc. now owns 96,808 shares of the medical instruments supplier’s stock worth $960,000 after acquiring an additional 13,217 shares in the last quarter. 89.43% of the stock is owned by institutional investors and hedge funds.

Key Stores Impacting AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Q2 revenue beat — AngioDynamics reported quarterly sales of about $79.4M (≈+9% YoY), above consensus, and gross profit expanded, signaling top-line momentum. Read More.
• Positive Sentiment: Operating cash flow improved materially — cash from operations rose to about $4.7M (≈+88% YoY), and management says it still expects to be cash-flow-positive for FY26, which supports near-term liquidity confidence. Read More.
• Positive Sentiment: FY26 guidance slightly ahead on revenue and in line/ modestly better on EPS range — the company set FY26 revenue guidance of $312–$314M versus consensus ≈$310.1M and gave an EPS range of −0.33 to −0.23 (consensus ≈−0.31), which reduces near-term downside to estimates. Read More.
• Positive Sentiment: Insider buying and institutional accumulation — recent insider purchases and notable hedge fund increases, plus several analyst buy ratings and price targets above the current price, may support longer-term demand. Read More.
• Neutral Sentiment: Market and media context — coverage includes earnings previews and snapshot pieces that summarize the quarter but add little new detail for valuation moves. Read More. • Read More.
• Neutral Sentiment: Increased visibility — ANGO was listed among “Top 5 stocks to watch” coverage today, which can drive short-term interest but not necessarily fundamentals. Read More.
• Neutral Sentiment: Broader market tone provided a modest tailwind (Dow record/highs), but sector-specific earnings are the main driver for ANGO today. Read More.
• Negative Sentiment: Profitability remains an issue — despite revenue strength, AngioDynamics posted an operating loss (~$6.1M) and a net loss (~$6.4M); diluted loss per share (~$0.15) missed narrower expectations, which likely pressured the stock. Read More.
• Negative Sentiment: Share reaction — investors sold into the mixed print (higher-than-average volume), reflecting concern that improvements in cash flow and revenue have not yet translated into consistent profitability.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.